Biogen Inc (NASDAQ:BIIB) Director Sells $308,429.25 in Stock

Biogen Inc (NASDAQ:BIIB) Director Brian S. Posner sold 1,055 shares of the company’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $292.35, for a total value of $308,429.25. Following the completion of the transaction, the director now directly owns 6,995 shares of the company’s stock, valued at approximately $2,044,988.25. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

NASDAQ BIIB opened at $289.52 on Friday. The stock has a market cap of $54.10 billion, a PE ratio of 11.05, a P/E/G ratio of 1.63 and a beta of 1.08. The company has a current ratio of 1.91, a quick ratio of 1.74 and a debt-to-equity ratio of 0.35. Biogen Inc has a twelve month low of $215.77 and a twelve month high of $344.00. The stock has a fifty day simple moving average of $284.23 and a 200-day simple moving average of $244.41.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Tuesday, October 22nd. The biotechnology company reported $9.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.27 by $0.90. The firm had revenue of $3.60 billion for the quarter, compared to analyst estimates of $3.53 billion. Biogen had a net margin of 37.91% and a return on equity of 46.14%. Biogen’s revenue was up 4.7% on a year-over-year basis. During the same period in the previous year, the firm earned $7.40 EPS. Research analysts predict that Biogen Inc will post 33.14 EPS for the current year.

A number of equities analysts have issued reports on BIIB shares. Cowen increased their price target on Biogen from $275.00 to $325.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 23rd. SunTrust Banks started coverage on Biogen in a report on Tuesday, November 12th. They issued a “buy” rating and a $337.00 price objective on the stock. Jefferies Financial Group boosted their price objective on Biogen from $255.00 to $310.00 and gave the company a “hold” rating in a research report on Tuesday, October 22nd. Sanford C. Bernstein raised Biogen from a “market perform” rating to an “outperform” rating in a research note on Tuesday, October 29th. Finally, Mizuho reiterated a “hold” rating and set a $235.00 target price on shares of Biogen in a research report on Tuesday, October 22nd. Five analysts have rated the stock with a sell rating, twenty-one have assigned a hold rating and ten have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $289.69.

A number of hedge funds have recently made changes to their positions in the business. Trustcore Financial Services LLC increased its holdings in Biogen by 152.3% in the 2nd quarter. Trustcore Financial Services LLC now owns 111 shares of the biotechnology company’s stock valued at $26,000 after purchasing an additional 67 shares during the last quarter. Bourgeon Capital Management LLC purchased a new position in shares of Biogen in the third quarter valued at approximately $30,000. Ruggie Capital Group acquired a new position in shares of Biogen in the second quarter valued at approximately $33,000. Resources Management Corp CT ADV purchased a new stake in Biogen during the 3rd quarter worth approximately $34,000. Finally, Next Capital Management LLC increased its stake in Biogen by 101.3% during the 2nd quarter. Next Capital Management LLC now owns 151 shares of the biotechnology company’s stock worth $35,000 after buying an additional 76 shares during the period. 87.47% of the stock is owned by institutional investors.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis.

Read More: Asset Allocation Models, Which is Right For You?

Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit